The Brexit Health Alliance submitted written evidence to the Health and Social Care Committee’s inquiry on Brexit: medicines, medical devices and substances of human origin.
Sir Hugh Taylor, co-chair of the Brexit Health Alliance was subsequently asked to provide oral evidence to the Committee on 17 December 2017.
The committee published its report on the inquiry on 21 March 2018, which draws heavily on the evidence provided by the Brexit Health Alliance and puts forward a number of insightful and pragmatic recommendations necessary to maintain public health and patient safety after the UK leaves the EU. The report calls for:
- maintenance of regulatory alignment with the European Medicines Agency
- continued UK participation in EU-wide clinical trials and research and development
- mutual recognition of pharmacovigilance mechanisms by the Medicines and Healthcare Regulatory Agency and the European Medicines Agency, to maintain patient safety, including continued membership of all of the major EU pharmacovigilance systems and databases
- free and frictionless trade with the EU to prevent any negative impact on current medicines' supply chains.
Read the full report.